Investors’ deep pessimism is actually bullish, and less regulatory constraint could fuel new drug approvals and M&A.

With improved market conditions, innovative breakthroughs, and more investor interest, the biotechnology industry is gaining new traction.

Story March 5 - ALX Oncology: As the biotech looks to channel its cash into further trials of its CD47 blocker, the company will lay off 30% of its workforce. Story March 5 - Bristol Myers Squibb ...

Sana Biotechnology Inc. concealed from investors that it was running low on money to continuing developing drug candidates ...

J&J will now pick up almost the full tab for the phase 3 trial, and, in return, Nanobiotix will see the potential milestone ...

Biotech is an area that may offer your portfolio growth today and earnings stability tomorrow. The idea is a biotech stock ...

Sinovac Biotech (SVA) shareholder Heng Ren Partners ... s Board of Directors must take to create liquidity and release cash to shareholders. Specifically, Heng Ren demands that Sinovac’s ...

1. Small-cap and midcap (smid-cap) biotech stocks recently traded at an enterprise-value to cash ratio of 1.2, according to biotech analyst Michael Yee at Jefferies. Historically, this group ...